Management of human epidermal growth factor receptor inhibitors‐related acneiform rash: A position paper based on the first Europe/ USA Delphi consensus process
Journal of the European Academy of Dermatology and Venereology · 2025-04 · 39 (4) · 730-741
DOI: 10.1111/jdv.20391 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 26.10.2024. Verfasst von Z Apalla und 34 weiteren Autor:innen. Beteiligte Einrichtung: Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: ErbB Receptors, Acneiform Eruptions. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.
Objective
To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.
Methods
The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force ‘Dermatology for Cancer Patients’ who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi‐induced acneiform rash. Experts responded to an anonymous 5‐point Likert scale survey. The coordinators collected the first‐round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second‐round survey.
Results
Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low‐dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid‐sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics.
Conclusion
This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Dermatology Service, Hospital Ruber Juan Bravo, and Universidad Europea, Madrid, Spain.
- Dermatology Department, Medical School of University of Patras, Rio, Greece.
- Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
- First Dermatology Department, National and Kapodistrian University of Athens, Athens, Greece.
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Z Apalla, A Freites-Martinez, K Grafanaki, A Ortiz-Brugues, V Nikolaou, D Fattore, P Sollena, N Kluger, M Beylot-Barry, M Sauder, C Carrera, M Starace, L Kraehenbuehl, M Fida, M Lacouture, V Sibaud
Förderung
- NCI NIH HHS
Zitieren
APA
Apalla, Z., Freites-Martinez, A., Grafanaki, K., Ortiz-Brugues, A., Nikolaou, V., Fattore, D., Sollena, P., Deverapalli, S., Babakoohi, S., Galimont, A., Kluger, N., Beylot-Barry, M., Larocca, C., Iriarte, C., Smith, J., Tattersall, I., Dodiuk-Gad, R., Sauder, M., Carrera, C., …, & Sibaud, V. (2025). Management of human epidermal growth factor receptor inhibitors‐related acneiform rash: A position paper based on the first Europe/ USA Delphi consensus process. Journal of the European Academy of Dermatology and Venereology, 39(4), 730-741. https://doi.org/10.1111/jdv.20391
Vancouver
Apalla Z, Freites-Martinez A, Grafanaki K, Ortiz-Brugues A, Nikolaou V, Fattore D, et al. Management of human epidermal growth factor receptor inhibitors‐related acneiform rash: A position paper based on the first Europe/ USA Delphi consensus process. Journal of the European Academy of Dermatology and Venereology. 2025;39(4):730-741. doi:10.1111/jdv.20391
BibTeX
@article{Apalla2025,
author = {Apalla, Z and Freites-Martinez, A and Grafanaki, K and Ortiz-Brugues, A and Nikolaou, V and Fattore, D and Sollena, P and Deverapalli, S and Babakoohi, S and Galimont, A and Kluger, N and Beylot-Barry, M and Larocca, C and Iriarte, C and Smith, J and Tattersall, I and Dodiuk-Gad, R and Sauder, M and Carrera, C and Kwong, B and Whitley, M and Leboeuf, N and Romano, P and Starace, M and Mateeva, V and Riganti, J and Hirner, J and Patel, A B and Reyes-Habito, C M and Kraehenbuehl, L and Kheterpal, M and Fida, M and Hassel, J and Lacouture, M and Sibaud, V},
title = {Management of human epidermal growth factor receptor inhibitors‐related acneiform rash: A position paper based on the first Europe/ USA Delphi consensus process},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {4},
pages = {730--741},
doi = {10.1111/jdv.20391}
}
EUVIMED